# Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer

> **NCT07737795** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University of Oklahoma** · enrollment: 66 (estimated)

## Conditions studied

- Endometrial Cancer

## Interventions

- **DRUG:** OK-1 & Paclitaxel

## Key facts

- **NCT ID:** NCT07737795
- **Lead sponsor:** University of Oklahoma
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2028-08
- **Final completion:** 2029-08
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2026-07-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07737795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07737795, "Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07737795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*